prolyl-leucyl-glycinamide

**Prolyl-leucyl-glycinamide** (PLG), also known as MIF-1, is a synthetic tripeptide consisting of L-proline, L-leucine, and glycine, with a C-terminal amide modification. It was originally discovered as a neuropeptide with activity as a melanocyte-stimulating hormone (MSH) release-inhibiting factor in the hypothalamus. PLG exerts neuroendocrine actions, and has significant modulatory effects on the central nervous system, notably as a positive allosteric modulator of the dopamine D2 receptor, influencing dopamine signaling. Experimental evidence also supports its role as an endogenous opioid antagonist and as a substance that reduces aggression and blocks defeat-induced opioid analgesia in animal models. PLG has been studied for possible use in the treatment of neurological and psychiatric disorders, such as Parkinson's disease and depression, due to its central dopamine-modulating properties[1][3][5].

Other names

Melanotropin-inhibiting factorMelanotropin release-inhibiting factorMelanostatin